Grapefruit juice and drugs: A hazardous association?;Jus de pamplemousse et médicaments: Une association à surveiller?

Therapie

Volumn 57, Issue 5, 2002, Pages 432-445

  Lohezic Le Devehat, F ^a   Marigny, K ^a   Doucet, M ^a   Javaudin, L ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Bioavailability; CYP 3A4; Drug interaction; Grapefruit juice; Pharmacokinetics

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; ALPRAZOLAM; AMLODIPINE; AURANTIIN; BERGAMOTTIN; CISAPRIDE; CLARITHROMYCIN; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIAZEPAM; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; FELODIPINE; FLAVONOID; FLUINDOSTATIN; FLUVOXAMINE; FUROCOUMARIN; GLYCOPROTEIN P; HALOPERIDOL; ITRACONAZOLE; MEVINOLIN; MIDAZOLAM; NARINGENIN; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; SESQUITERPENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG POTENTIATION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; PRIORITY JOURNAL; SIDE EFFECT; SMALL INTESTINE; TACHYCARDIA;

BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 ENZYME SYSTEM; FOOD-DRUG INTERACTIONS; HUMANS;

EID: 17144464602     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (150)

1. Janssens M. Les liaisons dangereuses. Impact Médecin Hebdo 1998; 431(4): 49
2. Internet. Summary of safety-related drug labeling changes aproved by FDA/Medwatch (the FDA medical products reporting program). In: http://www.fda.gov/medwatch/safety/1998/janv98.htm; 2001
3. Bailey DG, Spence JD, Edgar B, et al. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med 1989; 12(6): 357-62
4. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine [see comments]. Lancet 1991; 337(8736): 268-9
5. Bailey DG, Arnold JM, Strong HA, et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 1993; 54(6): 589-94
6. Ohnishi A, Matsuo H, Yamada S, et al. Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br J Pharmacol 2000; 130(6): 1369-77
7. Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestionpharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52(2): 139-45
8. Feldman E. How grapefruit juice potentiates drug bioavailability. Nutrition reviews 1998; 55: 398-400
9. Beaune P. Les cytochromes P450 humains. Thérapie 1993; 48: 521-526
10. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25(11): 1228-33
11. Lundahl J, Regardh CG, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995; 49(1-2): 61-7
12. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99(10): 2545-53
13. Ameer B, Weintraub RA, Johnson JV, et al. Flavanone absorption after naringin, hesperidin and citrus administration. Clin Pharmacol Ther 1996; 60(1): 34-40
14. Rashid J, Kinstry M, Renwick A, et al. Quercetin, an in vitro inhibitor of CYP 3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 1993; 36: 460-3
15. Guengerich FP, Kim DH. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990; 11(12): 2275-9
16. Roussef R. Nomolin. A new bitter component in grapefruit juice. J Agric Food Chem 1982; 30: 504-7
17. Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7(5): 391-6
18. Fukuda K, Ohta T, Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol Pharm Bull 1997; 20(5): 560-4
19. He K, lyer KR, Hayes RN, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11(4): 252-9
20. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999; 65(3): 237-44
21. Guo LQ, Taniguchi M, Xiao YQ, et al. Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 2000; 82(2): 122-9
22. Intosh CM, Mansell R, Roussef R. Distribution of limonin in the fruit tissues of nine grapefruit cultivars. J Agric Food Chem 1982; 30: 689-92
23. Roussef R, Martin S, Youtsey C. Quantitative survey of narirutin, hesperidin and neohesperidin in Citrus. J Agric Food Chem 1987; 35: 1027-30
24. Mansel R, McIntosh C, Vest S. An analysis of the limonin and naringin content of grapefruit juice samples collected from Florida state test houses. J Agric Food Chem 1983; 31: 156-62
25. Fukuda K, Guo L, Ohashi N, et al. Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J Chromatogr B Biomed Sci Appl 2000; 741(2): 195-203
26. Albach RF, Wutscher HK. Flavanonone content of whole grapefruit and juice as influenced by fruit development. J Rio Grande Valley Hort Soc 1988; 41: 89-93
27. Berhow M, Vandercook C. Biosynthesis of naringin and prunin in detached grapefruit. Phytochem 1989; 28: 1627-30
28. Castillo J, Benavente O, Rio JD. Hesperidin 7-O-glucoside and prunin in citrus species. A study of their quantitative distribution in immature fruits and as immediate precursors of Neohesperidin and naringin. J Agric Food Chem 1993; 41: 1920-4
29. Herzod P, Monselise S. Growth and development of grapefruits in two different climatic districts of Israël. Israel J Agric Res 1968; 18: 181-6
30. Albach RF, Redman GH, Cruse RR. Annual and seasonnal changes in naringin concentration of ruby red grapefruit juice. J Agric Food Chem 1981; 29(4): 808-11
31. Roussef R. Differentiating citrus juice using flavanone glycoside concentrations profiles. New York; 1988
32. Sami PS, Toma RB, Nelson DB, et al. Effects of debittering on grapefruit juice acceptance. Int J Food Sci Nutr 1997: 48(4): 237-42
33. Kimball D, Norman S. Processing effects during commercial debiterring of Californian navel orange juice. J Agric Food Chem 1990; 38: 1396-1400
34. Wilson C, Wagner C, Shaw P. Reduction of bitter components in grapefruit and navel orange juices with b-cyclodextrin polymers or XAD resins in a fluidized bed process. J Agric Food Chem 1989; 37: 14-8
35. Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions? Clin Pharmacol Ther 1995; 58(4): 365-73
36. Bailey DG, Kreeft JH, Munoz C, et al. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′-dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64(3): 248-56
37. Edwards DJ, Bemier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996; 59(13): 1025-30
38. Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. Clin Pharmacol Ther 2000; 67(6): 690
39. Guo LQ, Fukuda K, Ohta T, et al. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000; 28(7): 766-71
40. Tassaneeyakul W, Guo LQ, Fukuda K, et al. Inhibition selectivity of grape-fruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378(2): 356-63
41. Runkel M, Bourian M, Tegtmeier M, et al. The character of inhibition of the metabolism of 1,2-benzopyrone (coumarin) by grapefruit juice in human. Eur J Clin Pharmacol 1997; 53(3-4): 265-9
42. Soldner A, Christians U, Susanto M, et al. Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res 1999; 16(4): 478-85
43. Takanaga H, Ohnishi A, Matsuo H, et al. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 1998; 21(10): 1062-6
44. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 346(8967): 122-3; discussion 123-4
45. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345(8955): 955-6
46. Mohri K, Uesawa Y, Sagawa K. Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. Drug Metab Dispos 2000; 28(4): 482-6
47. Leenen F, Logan A, Myers M, et al. Nifedipine, hypotension and myocardical injury. Letter, Annuals of internal medicine 1988; 108: 305-6
48. Anonymous. Pharmacokinetics and biotransformation of 1-4 dihydropyridine calcium antagonists. Progress in drug metabolism 1990; 12: 41-86
49. Hashimoto K, Shirafuji T, Sekino H, et al. Interaction of citrus juices with pranidipine, a new 1,4-dihydropyridine calcium antagonist, in healthy subjects. Eur J Clin Pharmacol 1998; 54(9-10): 753-60
50. Friedel HA. Nisoldipine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988; 36: 682-731
51. Goa KL. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987; 33: 123-55
52. Sorkin EM. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and efficacy in ischemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 184-274
53. Fuhr U, Maier-Bruggemann A, Blume H, et al. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36(3): 126-32
54. Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000; 67(3): 201-14
55. Josefsson M, Zackrisson AL, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol 1996; 51(2): 189-93
56. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68(1): 28-34
57. Soons PA, Vogels BA, Roosemalen MC, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50(4): 394-403
58. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41-57
59. Benton RE, Honig PK, Zamani K, et al. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59(4): 383-8
60. Honig PK, Wortham DC, Lazarev A, et al. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36(4): 345-51
61. Clifford CP, Adams DA, Murray S, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52(4): 311-5
62. Rau SE, Bend JR, Arnold MO, et al. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61(4): 401-9
63. Garg SK, Kumar N, Bhargava VK, et al. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther 1998; 64(3): 286-8
64. Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000; 39(1): 49-75
65. Gross AS, Goh YD, Addison RS, et al. Influence of grapefruit juice on cisapride pharmacokinetics. Clin Pharmacol Ther 1999; 65(4): 395-401
66. Kivisto KT, Lilja JJ, Backman JT, et al. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. Clin Pharmacol Ther 1999; 66(5): 448-53
67. Proppe D. Grapefruit juice selectively modifies cyclosporin A metabolite patterns in renal transplant patients. Clin Pharmacol Ther 1996; 59: 138
68. Herlitz H, Edgar B, Hedner T, et al. Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A. Nephrol Dial Transplant 1993: 8(4): 375
69. Ducharme M, Provenzano R, Dehome-Smith M, et al. Through concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-9
70. Hollander AA, Van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57(3): 318-24
71. Proppe DG, Hoch OD, McLean AJ, et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol 1995; 39(3): 337-8
72. Min DI, Ku YM, Perry PJ. et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996; 62(1): 123-5
73. Brunner LJ, Munar MY, Vallian J, et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18(1): 23-9
74. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57(5): 485-91
75. Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 1998; 38(10): 959-65
76. Ioannides-Demos L, Christophidis N, Ryan P, et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolites concentrations in patients with autoimmune diseases. J Rheumatol 1997; 24: 49-54
77. Bennett WM. What is the effect of grapefruit juice on cyclosporine pharmacokinetics? Pediatr Nephrol 1995; 9(1): 10
78. Emilia G, Longo G, Bertesi M, et al. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? Blood 1998; 91(1): 362-3
79. Taniguchi S, Kobayashi H, Ishii M. Treatment of psoriasis by cyclosporine and grapefruit juice. Arch Dermatol 1996; 132(10): 1249
80. Lampen A, Uwe C, Guengerich F. Metabolism of the immunosupressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. Drug Metab Dispos 1995; (23): 1315-24
81. Floren L, Bekersky I, Benet L. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-9
82. Lilja JJ, Kivisto KT, Backman JT, et al. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 1998; 64(6): 655-60
83. Ozdemir M, Aktan Y, Boydag BS, et al. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998; 23(1): 55-9
84. Ha HR, Chen J, Leuenberger PM, et al. In vitro inhibition of midazolam and quinidine metabolism by flavonoids. Eur J Clin Pharmacol 1995; 48(5): 367-71
85. Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58(1): 20-8
86. Hukkinen SK, Varhe A, Olkkola KT, et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58(2): 127-31
87. Vanakoski J, Mattila MJ, Seppala T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 1996; 50(6): 501-8
88. Thummel K, Paine M. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502
89. Ubeaud G, Hagenbach J, Vandenschrieck S, et al. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci 1999: 65(13): 1403-12
90. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66(2): 118-27
91. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63(4): 397-402
92. Rogers JD, Zhao J, Liu L, et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther 1999; 66(4): 358-66
93. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64(5): 477-83
94. Kivisto K, Kantola T, Neuvonen P. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53
95. Neuvonen P, Kantola T, Kivisto K. Simvastatin but not pravastatin is very susceptible to interaction with CYP3A4 inhibitor itraconazole. Clin Pharmacother 1998; 63: 332-341
96. Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: shifting metabolitic ratios. J Clin Psychopharmacol 1997; 17(1): 62-3
97. Vandel P, Regina W, Reix I, et al. Grapefruit juice as a contraindication? An approach in psychiatry. Encephale 1999; 25(1): 67-71
98. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of anliodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49(4): 373-8
99. Anonyme. Interactions entre inhibiteurs de la protéase et le jus de pample-mousse. Prescrire 1999; 9: 907-8
100. Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 1999; 48(4): 543-52
101. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45(4): 355-9
102. James J. Grapefruit juice and saquinavir. AIDS treatment news 1995; 235: 5-6
103. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46(2): 101-10
104. Crea M. Effects on ketoconazole and others P450 inhibitors on the pharmacokinetics of Indinavir. Pharma Res 1996; 13: 485
105. Anonymous. Crixivan capsules. USA: CCIS Medical Economics Company; 1999
106. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol 1993; 35(4): 431-6
107. Fuhr U, Maier A, Keller A, et al. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther 1995: 33(6): 311-4
108. Gupta MC, Garg SK, Badyal D, et al. Effect of grapefruit juice on the pharmacokinetics of theophylline in healthy male volunteers. Methods Find Exp Clin Pharmacol 1999; 21(10): 679-82
109. Maish WA, Hampton EM, Whitsett TL, et al. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy 1996; 16(6): 1046-52
110. Kawakami M, Suzuki K, Ishizuka T, et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 1998; 36(6): 306-8
111. Penzak SR, Gubbins PO, Gurley BJ, et al. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 1999; 21(3): 304-9
112. Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health Syst Pharm 1998; 55(15): 1581-3
113. Bartle WR. Grapefruit juice might still be factor in warfarin response. Am J Health Syst Pharm 1999; 56(7): 676
114. Lee AJ, Chan WK, Harralson AF, et al. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin Ther 1999; 21(11): 1890-9
115. Wiens A. How does grapefruit juice affect psychotropic medications? J Psychiatry Neurosci 2000; 25(2): 198
116. Weber A, Jager R, Borner A. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 1996; janv 53(1): 41-7
117. Schubert W, Cullberg G, Edgar B, et al. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas 1994; 20(2-3): 155-63
118. Schubert W, Eriksson U, Edgar B, et al. Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17 beta-estradiol. Eur J Drug Metab Pharmacokinet 1995: 20(3): 219-24
119. Seidegard J, Dahlstrom K, Kullberg A. Effect of grapefruit juice on urinary 6 beta-hydroxycortisol/cortisol excretion. Clin Exp Pharmacol Physiol 1998; 25(5): 379-81
120. Lee YS, Lorenzo BJ, Koufis T. et al. Grapefruit juice and its flavonoids inhibit beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996; 59(1): 62-71
121. Fuhr U, Harder S, Lopez-Rojas P. Increase of verapamil concentrations in steady-state by coadministration of grapefruit juice. Arch Pharmacol 1994; R134: 349
122. Zaidenstein R, Dishi V, Gips M, et al. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol 1998; 54(4): 337-40
123. Cheng KL, Nafziger AN, Peloquin CA, et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998; 42(4): 927-9
124. Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol 2000; 49(2): 139-44
125. Damkier P, Hansen LL, Brosen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999; 48(6): 829-38
126. Min DI, Ku YM, Geraets DR, et al. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol 1996; 36(5): 469-76
127. Ho PC, Chalcroft SC, Coville PF, et al. Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol 1999; 55(5): 393-8
128. Yasui N, Kondo T, Suzuki A, et al. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Int Clin Psychopharmacol 1999; 14(2): 113-8
129. Yasui N, Kondo T, Furukori H, et al. Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 2000: 150(2): 185-90
130. Kumar N, Garg SK, Prabhakar S. Lack of pharmacokinetic interaction between grapefruit juice and phenytoin in healthy male volunteers and epileptic patients. Methods Find Exp Clin Pharmacol 1999; 21(9): 629-32
131. Sigusch H, Henschel L, Kraul H, et al. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie 1994; 49(9): 675-9
132. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Editorial Circulation 1991; 84: 2599-600
133. Anonymous. Grapefruit juice interactions with drugs. Med Lett Drugs Ther 1995; 37(955): 73-4
134. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998; 18(4): 251-72
135. Ho PC, Saville DJ, Coville PF, et al. Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products. Pharm Acta Helv 2000; 74(4): 379-85
136. Lee YS, Reidenberg MM. A method for measuring naringenin in biological fluids and its disposition from grapefruit juice by man. Pharmacology 1998; 56(6): 314-7
137. Spence D. Drug interactions with grapefruit juice: whose responsability is to warn the public? Clin Pharmacol Ther 1997; 61: 395-400
138. Spence D. Drugs and grapefruit juice. Clin Pharmacol Ther 1998: 87-8
139. Gunston GD, Mehta U. Potentially serious drug interactions with grapefruit juice. S Afr Med J 2000; 90(1): 41
140. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75(9): 933-42
141. Lilley L, Guanci R. Grapefruit and medication. AJN 1998; 98: 12
142. Edgar B, Bailey D, Bergstrand R, et al. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine-and its potential clinical relevance. Eur J Clin Pharmacol 1992; 42(3): 313-7
143. Bailey DG, Arnold JM, Munoz C, et al. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993; 53(6): 637-42
144. Bailey DG, Arnold JM, Bend JR, et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995; 40(2): 135-40
145. Bailey DG, Bend JR, Arnold JM, et al. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996; 60(1): 25-33
146. Lundahl JU, Regardh CG, Edgar B, et al. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 1998; 54(1): 75-81
147. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40(1): 51-8
148. Sigusch H, Hippius M, Henschel L, et al. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie 1994; 49(7): 522-4
149. Fuhr U, Maier A, Blume H. Grapefruit juice increases oral nimodipine bioavailability. Eur J Clin Pharmacol 1994; 47: A100
150. Bailey D, Munoz C, Arnold J, et al. Grapefruit juice and naringin interaction with nitrendipine. Clin Pharmacol Ther 1992; 51: 156